Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1986-10-30
1989-11-14
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514533, 514539, 514562, 514563, 514564, 514565, 514597, 514608, 514629, 514630, 514651, 514620, 514653, A61K 31195, A61K 31235, A61K 31195, A61K 3116
Patent
active
048808342
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to the use of certain ethanolamine derivatives in a method for increasing weight gain and/or improving the feed utilisation efficiency and/or increasing the lean body mass and/or decreasing birth mortality rate and increasing post-natal survival rate; of livestock and the veterinary formulations comprising such compounds.
European Published Patent Application No. 0,006,735 discloses compounds of general formula (I): ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is a hydrogen, fluorine or chlorine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R.sup.2 is a hydrogen, fluorine or chlorine atom or a hydroxyl group; R.sup.3 is a hydrogen or chlorine atom or a hydroxyl group; R.sup.4 is a carboxylic acid group or a salt, ester or amide thereof; R.sup.5 is a hydrogen, chlorine or fluorine atom or a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof; R.sup.6 is a hydrogen atom or a methyl, ethyl or propyl group; R.sup.7 is a hydrogen atom or a methyl, ethyl or propyl group; X is an oxygen atom or a bond; and Y is an alkylene group of up to 6 carbon atoms or a bond; which compounds show anti-obesity and/or anti-hyperglycaemic activity.
European Patent Specification No. 0,023,385 discloses compounds of a general formula (II): ##STR2## or a pharmaceutically acceptable salt, ester or amide thereof wherein R.sup.1A is a hydrogen, fluorine or chlorine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R.sup.2A is a hydrogen, fluorine or chlorine atom or a hydroxyl group; R.sup.3A is a hydrogen or chlorine atom or a hydroxyl group; or R.sup.1A, R.sup.2A, and R.sup.3A each represents a bromine atom; R.sup.4A is a hydrogen atom or a methyl group; R.sup.5A is a hydrogen atom or a methyl group; R.sup.6A is a hydrogen, fluorine or chlorine atom or a methyl, methoxyl or hydroxy group; X.sup.1 is an oxygen atom or a bond; Y.sup.1 is an alkylene group of up to 6 carbon atoms or a bond; and Z is an alkylene, alkenylene or alkynylene group of up to 10 carbon atoms; which compounds show anti-obesity and/or anti-hyperglycaemic activity.
European patent specification No. 0,028,105 discloses a particular group of compounds, falling within formula (I), of formula (III): ##STR3## and esters, amides and pharmaceutically acceptable salts thereof wherein A.sup.1 is a hydrogen atom or a methyl group and A.sup.2 is a hydrogen atom or a methyl group and a is 1,2 or 3.
The compounds of formula (III) are described as having good anti-obesity and anti-glycaemic properties coupled with low side effects.
European patent specification No. 0,040,915 also discloses a particular group of compounds, falling within formula (I), of formula (IV) ##STR4## or a pharmaceutically acceptable salt, lower alkyl or aralkyl ester or amide thereof, wherein R.sup.1B and R.sup.2B which may be the same of different, are each a hydrogen atom or a methyl group, b is 1,2 or 3, and Z.sup.1 is a C.sub.1-6 alkyl or C.sub.1-6 alkoxy group, or a halogen or hydrogen atom.
The compounds of formula (IV) are described as having anti-obesity and/or hypoglycaemic activity coupled with low cardiac stimulant activity. Particular compounds of formula (IV) also have anti-inflammatory activity.
European patent specification No. 0,040,000 discloses compounds of formula (V): ##STR5## or a pharmaceutically acceptable salt thereof, in which X.sup.2 is an oxygen atom or a bond, R.sup.1C is a hydrogen, fluorine, chlorine or bromine atom or a trifluoromethyl or C.sub.1-4 alkyl group, each of R.sup.2C and R.sup.3C is a hydrogen atom or a C.sub.1-4 alkyl group, R.sup.4C is a C.sub.1-4 alkyl group, R.sup.5C is a hydrogen atom or a C.sub.1-4 alkyl group and c is an integer of from 1 to 3.
The compounds
REFERENCES:
patent: 4146638 (1979-03-01), Renth et al.
patent: 4404222 (1983-09-01), Baker
patent: 4654371 (1987-03-01), Ainsworth et al.
Blodinger-Formulation of Veterinary Dosage Forms, 1983, Marcel Deckker, Inc, New York and Basel, pp. 176-189.
The Merck Veterinary Manual, Fifth Edition, Merck & Co. Inc., Rahway, N.J., U.S.A., 1979, pp. 201, 202, 524 & 525.
Chemical Abstracts, vol. 94, 1981, 15371m.
Beecham Group p.l.c.
Waddell Frederick E.
LandOfFree
Method for administering ethanolamine derivatives to livestock does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for administering ethanolamine derivatives to livestock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for administering ethanolamine derivatives to livestock will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853256